Alpha 2.0
Login Register
» Articles » PMID: 33758394

Using Buprenorphine to Treat Neonatal Abstinence Syndrome: a Quality Improvement Study

Overview
Journal J Perinatol
Specialty Gynecology & Obstetrics
Date 2021 Mar 24
PMID 33758394
Citations 3
Authors
Sagar Bhandary
Tinisha Lambeth
Amy Holmes
Mary Pylipow
Affiliations
Soon will be listed here.
Abstract

Objective: To assess if treating neonatal abstinence syndrome (NAS) with sublingual buprenorphine (SLB) would decrease the mean duration of therapy (DOT) and length of birth hospital stay (LOS).

Study Design: Conducted at a tertiary hospital with >6000 annual deliveries and a 2% incidence of NAS, a quality improvement study using plan-do-study-act (PDSA) cycles were utilized. Outcomes were measured using statistical process control (SPC) charts.

Results: All NAS patients were treated with SLB, no adverse reactions were reported and the need for an adjunctive agent was static. SPC charts demonstrated decreased variability and special cause variation indicating a reduction in both DOT (from 14.5 to 8.5 days) and LOS (from 18.5 to 13 days).

Citing Articles

Buprenorphine vs. morphine: impact on neonatal opioid withdrawal syndrome (NOWS) outcomes in a single center retrospective study.

Anbalagan S, Anderson V, Favara M, Stark D, Carola D, Solarin K J Perinatol. 2024; .

PMID: 39003405 DOI: 10.1038/s41372-024-02046-7.

The Bioavailability of CHF6563, an Ethanol-Free, Sublingual Neonatal Buprenorphine Formulation: A Bridging Study Conducted in Adults.

Kraft W, Barneschi I, Bocchi M, Santoro D, Cella M J Pediatr Pharmacol Ther. 2024; 29(1):49-52.

PMID: 38332965 PMC: 10849686. DOI: 10.5863/1551-6776-29.1.49.

Stability Study of a Compounded Sublingual Buprenorphine Solution for Neonatal Opioid Withdrawal Syndrome.

Ahmadi A, Cutaia D, Perkins J, Zhao F, Gawronski K, Austin D J Pediatr Pharmacol Ther. 2023; 28(8):710-713.

PMID: 38094678 PMC: 10715386. DOI: 10.5863/1551-6776-28.8.710.

References
1.
Kocherlakota P . Neonatal abstinence syndrome. Pediatrics. 2014; 134(2):e547-61. DOI: 10.1542/peds.2013-3524. View
2.
Winkelman T, Villapiano N, Kozhimannil K, Davis M, Patrick S . Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid: 20042014. Pediatrics. 2018; 141(4). PMC: 5869343. DOI: 10.1542/peds.2017-3520. View
3.
Jones H, Kaltenbach K, Heil S, Stine S, Coyle M, Arria A . Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010; 363(24):2320-31. PMC: 3073631. DOI: 10.1056/NEJMoa1005359. View
4.
Coyle M, Salisbury A, Lester B, Jones H, Lin H, Graf-Rohrmeister K . Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. 2012; 107 Suppl 1:63-73. PMC: 4337995. DOI: 10.1111/j.1360-0443.2012.04040.x. View
5.
Bier J, Finger A, Bier B, Johnson T, Coyle M . Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine. J Perinatol. 2015; 35(8):656-9. DOI: 10.1038/jp.2015.22. View